NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
RADNOR, Pa., May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2024 financial results after the market closes on Tuesday, May 14, 2024, via press release, which will be available on the Company's website at . The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.
賓夕法尼亞州拉德諾，2024年5月7日 /PRNewswire/ — 處於臨床階段的生物製藥公司nRx Pharmicals, Inc.（納斯達克股票代碼：NRXP）（“nrX Pharmicals”，“公司”）今天宣佈，將在2024年5月14日星期二收盤後通過新聞稿發佈其2024年第一季度財務業績，該新聞稿將在公司網站上公佈 。該公司將在美國東部時間當天下午 4:30 舉行電話會議，討論財務業績，並提供公司最新情況。
A live webcast of the conference call will be available on the Company's website at Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
電話會議的網絡直播將在公司網站上提供，無法參加網絡直播的參與者可以通過電話撥打國內+1-800-717-1738或國際電話+1-646-307-1865來觀看電話會議。
About NRx Pharmaceuticals
關於 nRx 製藥
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
nRx Pharmaceuticals是一家臨床階段的生物製藥公司，基於其NMDA平台開發治療中樞神經系統疾病的療法，特別是自殺性雙相抑鬱症、慢性疼痛和創傷後應激障礙。該公司正在開發 NRX-101，這是一種美國食品藥品管理局指定的研究性突破性療法，用於治療耐自殺性雙相抑鬱症和慢性疼痛。nRx 已與 Alvogen 和 Lotus 合作，開發和銷售用於治療自殺性雙相抑鬱症的 NRX-101。此外，NRX-101 有可能作爲慢性疼痛的非阿片類藥物治療以及複雜尿路感染的治療方法。
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx最近宣佈計劃通過Hope Therapeutics提交用於治療自殺性抑鬱症的 HTX-100（靜脈****）新藥申請，該申請基於在美國國立衛生研究院主持下進行的對照良好的臨床試驗結果以及根據數據共享協議獲得許可的法國衛生當局新獲得的數據。作爲治療急性自殺患者的協議的一部分，nRx被美國食品藥品管理局授予****（NRX-100）開發快速通道稱號。
About HOPE Therapeutics, Inc.
關於HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. () is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
HOPE Therapeutics, Inc. () 是一家專業製藥公司，由NRX Pharmicals全資擁有，專注於開發和銷售一種經美國食品藥品管理局批准的用於治療急性自殺和抑鬱症的靜脈注射****，以及一個支持數字療法的平台，旨在增強和保持NMDA靶向藥物療法的臨床益處。
SOURCE NRx Pharmaceuticals, Inc.
來源 nRx Pharmicals, Inc.
譯文內容由第三人軟體翻譯。